News
Shares of Sarepta Therapeutics declined 17% in early trading on Friday after another patient who had received an experimental ...
The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...
Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...
Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results